DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR NEO-MEDROL
All Clinical Trials for Neo-medrol
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00023231 | Pediatric Kidney Transplant Without Calcineurin Inhibitors | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | N/A | 2001-02-01 | The purpose of this study is to see the effect of using drugs other than calcineurin inhibitors to improve the rate of kidney transplant failure. Kidney transplantation can help children with end-stage kidney disease. However, it has been difficult to find treatment for donor graft rejection that does not have a lot of side effects. Researchers hope to find treatments (immunosuppressants) with fewer side effects. One approach is to avoid using calcineurin inhibitors and to try a new drug known as sirolimus instead. Another is to use steroids less often. This study will test whether using sirolimus, fewer steroid treatments, MMF, and certain antibodies will improve long-term graft survival in children receiving kidney transplants from living donors. |
| NCT00104299 | Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis | Completed | Genentech, Inc. | Phase 2/Phase 3 | 2005-01-01 | Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis is the most common type of small blood vessel inflammation in adults. ANCA-associated vasculitis includes Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA). Rituximab is a man-made antibody used to treat certain types of cancer. The purpose of this study is to determine the effectiveness of rituximab in treating patients with WG and MPA. Study hypothesis: Rituximab is not inferior to conventional therapy in its ability to induce disease remission by Month 6. |
| NCT00104299 | Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis | Completed | Immune Tolerance Network (ITN) | Phase 2/Phase 3 | 2005-01-01 | Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis is the most common type of small blood vessel inflammation in adults. ANCA-associated vasculitis includes Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA). Rituximab is a man-made antibody used to treat certain types of cancer. The purpose of this study is to determine the effectiveness of rituximab in treating patients with WG and MPA. Study hypothesis: Rituximab is not inferior to conventional therapy in its ability to induce disease remission by Month 6. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Neo-medrol
Condition Name
Condition MeSH
Clinical Trial Locations for Neo-medrol
Trials by Country
Clinical Trial Progress for Neo-medrol
Clinical Trial Phase
Clinical Trial Sponsors for Neo-medrol
Sponsor Name
